We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Antipsychotic Prescription in Children and Adolescents.
- Authors
Bachmann, Christian J.; Lempp, Thomas; Glaeske, Gerd; Hoffmann, Falk
- Abstract
Background: Despite sparse documentation of their long-term therapeutic effects and side effects, antipsychotic drugs have come to be prescribed more frequently for children and adolescents in recent years, both in the USA and in Europe. No current data are available about antipsychotic prescriptions for this age group in Germany. Methods: Data from the largest statutory health insurance fund in Germany (BARMER GEK) were studied to identify antipsychotic prescriptions for children and adolescents (age 0-19 years) from 2005 to 2012 and analyze them with respect to age, sex, drug prescribed, prescribing medical specialty, and any observable secular trends. Results: The percentage of children and adolescents receiving a prescription for an antipsychotic drug rose from 0.23% in 2005 to 0.32% in 2012. In particular, atypical antipsychotic drugs were prescribed more frequently over time (from 0.10% in 2005 to 0.24% in 2012). The rise in antipsychotic prescriptions was particularly marked among 10- to 14-year-olds (from 0.24% to 0.43%) and among 15- to 19-year-olds (from 0.34% to 0.54%). The prescribing physicians were mostly either child and adolescent psychiatrists or pediatricians; the most commonly prescribed drugs were risperidone and pipamperone. Risperidone was most commonly prescribed for patients with hyperkinetic disorders and conduct disorders. Conclusion: In Germany as in other industrialized countries, antipsychotic drugs have come to be prescribed more frequently for children and adolescents in recent years. The German figures, while still lower than those from North America, are in the middle range of figures from European countries. The causes of the increase should be critically examined; if appropriate, the introduction of prescribing guidelines of a more restrictive nature could be considered.
- Subjects
GERMANY; ANTIPSYCHOTIC agents; CHILD patients; DRUG side effects; RISPERIDONE; CHILD psychiatry; ADOLESCENT psychiatry
- Publication
Deutsches Ärzteblatt International, 2014, Vol 111, Issue 3, p25
- ISSN
1866-0452
- Publication type
Article
- DOI
10.3238/arztebl.2014.0025